Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Prostate Cancer Epidemiology

  • Randall E. Harris
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6791-2


Prostate cancer is the second most common form of cancer in men and the fifth leading cause of cancer deaths worldwide. In 2012, 1.12 million new cases of prostate cancer were diagnosed and 307,000 men died of the disease. During 2000-2012, the volume of new cases doubled and the number of deaths from prostate cancer increased by 50 %. As discussed in this chapter, multiple factors have influenced the surging global burden of prostate cancer including dietary changes leading to higher levels of obesity and inflammation that increase the risk and more sensitive methods of diagnosis (Harris 2016).


Global Epidemiology of Prostate Cancer

In developed countries, prostate cancer is diagnosed more often than any other form of male cancer (nearly 760,000 cases) and is the third leading cause of death from cancer in men (142,000 deaths annually). Disease survival in developing countries is high, and the ratio of incidence to mortality is 0.19 which is primarily due to...


Prostate Cancer Androgen Receptor Benign Prostate Hyperplasia Prostate Gland Prostate Carcinogenesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Andriole GL et al (2009) Mortality results from a randomized prostate-cancer screening trial. NEJM 360(13):1310–1319CrossRefPubMedPubMedCentralGoogle Scholar
  2. De Angelis G, Rittenhouse HG, Mikolajczyk SD, Blair Shamel L, Semjonow A (2007) Twenty years of PSA: from prostate antigen to tumor marker. Rev Urol 9(3):113–123PubMedPubMedCentralGoogle Scholar
  3. Giovannucci E, Eric B, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, Willett WC (1993) A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85(19):1571–1579CrossRefPubMedGoogle Scholar
  4. Harris RE (2007) COX-2 and the inflammogenesis of cancer. Subcell Biochem 42:193–212CrossRefPubMedGoogle Scholar
  5. Harris RE (2016) Epidemiology of prostate cancer. In “Global Epidemiology of Cancer”, Chapter 16, pp. 211–220, Jones & Bartlett Learning, Burlington, MA, USAGoogle Scholar
  6. McNeal J (1981) Normal and pathologic anatomy of prostate. Urology 17(Suppl 3):11–16PubMedGoogle Scholar
  7. McNeal J (1993) Prostatic microcarcinomas in relation to cancer origin and the evolution to clinical cancer. Cancer 71:984–991CrossRefPubMedGoogle Scholar
  8. Meikle AW, Stanish WM (1982) Familial prostatic cancer risk and low testosterone. J Clin Endocrinol Metab 54:1104–1108CrossRefPubMedGoogle Scholar
  9. Parkin MD, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMedGoogle Scholar
  10. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE (1992) 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339(8798):887–889CrossRefPubMedGoogle Scholar
  11. Schröder FH et al (2009) Screening and prostate cancer mortality in a randomized European study. NEJM 360(13):1320CrossRefPubMedGoogle Scholar
  12. Thompson IM, Goodman PJ, Tangen CM et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224CrossRefPubMedGoogle Scholar
  13. US Preventive Services Task Force (2008) Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 149(3):185–191CrossRefGoogle Scholar
  14. Zhu YS (2005) Molecular basis of steroid action in the prostate. Cellscience 1:27–55PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Director Center of Molecular EpidemiologyThe Ohio State UniversityColombusUSA